A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions

HealthyPain

Interventions

DRUG

MK-4318

Oral administration

DRUG

Diltiazem

Oral administration

Trial Locations (1)

Labcorb CRU, Madison (Site 0001), Madison

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06692647 - A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003) | Biotech Hunter | Biotech Hunter